Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All curcumin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Progression 92% Improvement Relative Risk Hospitalization time 25% Chest CT score 68% Recovery, dyspnea/oxygen.. 67% Recovery, fever 80% Recovery, cough 86% Recovery, headache 80% Recovery, fatigue 75% Recovery, myalgia 75% Recovery, diarrhea 67% Recovery, inappetence 50% Recovery, nausea 67% Curcumin  Sadeghizadeh et al.  LATE TREATMENT  DB RCT Is late treatment with curcumin beneficial for COVID-19? Double-blind RCT 42 patients in Iran Lower progression (p=0.021) and shorter hospitalization (p=0.0069) c19early.org Sadeghizadeh et al., Phytotherapy Rese.., Apr 2023 Favors curcumin Favors control

Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID‐19 patients: A randomized, double‐blinded, placebo‐controlled trial

Sadeghizadeh et al., Phytotherapy Research, doi:10.1002/ptr.7844, IRCT20170128032241N3
Apr 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
RCT 42 hospitalized moderate/severe COVID-19 patients in Iran, showing lower progression and improved recovery with nano-curcumin. Nano-curcumin 70mg bid for 14 days.
This is the 18th of 20 COVID-19 RCTs for curcumin, which collectively show efficacy with p=0.0000093.
This is the 24th of 26 COVID-19 controlled studies for curcumin, which collectively show efficacy with p=0.000000046 (1 in 22 million).
risk of progression, 92.3% lower, RR 0.08, p = 0.02, treatment 0 of 21 (0.0%), control 6 of 21 (28.6%), NNT 3.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 24.5% lower, relative time 0.75, p = 0.007, treatment mean 7.7 (±2.3) n=21, control mean 10.2 (±3.3) n=21.
relative chest CT score, 67.5% better, RR 0.33, p < 0.001, treatment mean 1.3 (±0.82) n=21, control mean 4.0 (±1.8) n=21, day 14.
risk of no recovery, 66.7% lower, RR 0.33, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 21 (14.3%), NNT 10, day 14, dyspnea/oxygen need.
risk of no recovery, 80.0% lower, RR 0.20, p = 0.18, treatment 1 of 21 (4.8%), control 5 of 21 (23.8%), NNT 5.2, day 14, fever.
risk of no recovery, 85.7% lower, RR 0.14, p = 0.04, treatment 1 of 21 (4.8%), control 7 of 21 (33.3%), NNT 3.5, day 14, cough.
risk of no recovery, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 21 (9.5%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, headache.
risk of no recovery, 75.0% lower, RR 0.25, p = 0.34, treatment 1 of 21 (4.8%), control 4 of 21 (19.0%), NNT 7.0, day 14, fatigue.
risk of no recovery, 75.0% lower, RR 0.25, p = 0.34, treatment 1 of 21 (4.8%), control 4 of 21 (19.0%), NNT 7.0, day 14, myalgia.
risk of no recovery, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), NNT 21, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, diarrhea.
risk of no recovery, 50.0% lower, RR 0.50, p = 1.00, treatment 1 of 21 (4.8%), control 2 of 21 (9.5%), NNT 21, day 14, inappetence.
risk of no recovery, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), NNT 21, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, nausea.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sadeghizadeh et al., 29 Apr 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 12 authors, trial IRCT20170128032241N3.
This PaperCurcuminAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit